Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2008

01-03-2008 | Original Article

Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning

Authors: Qing-An Yuan, Matthew K. Robinson, Heidi H. Simmons, Maria Russeva, Gregory P. Adams

Published in: Cancer Immunology, Immunotherapy | Issue 3/2008

Login to get access

Abstract

While cell surface antigens represent the most common targets for antibody-based cancer therapy, isolation of new antibodies specific for these targets from single-chain Fv phage display libraries has been hindered by limitations associated with traditional selection techniques. Solid phase panning is often associated with conformational changes to the target protein due to its immobilization on plastic tubes that can limit the ability of the isolated scFv to bind to conformational epitopes and solution panning methods require the use of secondary tags that often mask desired sequences and create unintended epitopes. Commonly utilized cell-based panning methods typically yield a panel of single-chain Fv (scFv) molecules that are specific for numerous cell surface antigens, often obscuring the desired clones. Here, we describe a novel cell sorter-based system to isolate single-chain Fv molecules specific for defined antigen targets expressed on stably-transformed mammalian cells. We employed these methods to isolate promising scFv clones that bind specifically to the Müllerian inhibiting substance type II receptor, a cell surface ovarian cancer antigen that has proven to be a difficult target for selection strategies.
Literature
1.
go back to reference Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM (1998) Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58:485–490PubMed Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM (1998) Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58:485–490PubMed
2.
3.
go back to reference Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP, Grootegoed JA (1995) Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 136:4951–4962PubMedCrossRef Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP, Grootegoed JA (1995) Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 136:4951–4962PubMedCrossRef
4.
go back to reference Baarends WM, van Helmond MJ, Post M, van der Schoot PJ, Hoogerbrugge JW, de Winter JP, Uilenbroek JT, Karels B, Wilming LG, Meijers JH et al (1994) A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mullerian duct. Development 120:189–197PubMed Baarends WM, van Helmond MJ, Post M, van der Schoot PJ, Hoogerbrugge JW, de Winter JP, Uilenbroek JT, Karels B, Wilming LG, Meijers JH et al (1994) A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mullerian duct. Development 120:189–197PubMed
5.
go back to reference Butler JE, Navarro P, Sun J (1997) Adsorption-induced antigenic changes and their significance in ELISA and immunological disorders. Immunol Invest 26:39–54PubMedCrossRef Butler JE, Navarro P, Sun J (1997) Adsorption-induced antigenic changes and their significance in ELISA and immunological disorders. Immunol Invest 26:39–54PubMedCrossRef
6.
go back to reference Butler JE, Ni L, Nessler R, Joshi KS, Suter M, Rosenberg B, Chang J, Brown WR, Cantarero LA (1992) The physical and functional behavior of capture antibodies adsorbed on polystyrene. J Immunol Methods 150:77–90PubMedCrossRef Butler JE, Ni L, Nessler R, Joshi KS, Suter M, Rosenberg B, Chang J, Brown WR, Cantarero LA (1992) The physical and functional behavior of capture antibodies adsorbed on polystyrene. J Immunol Methods 150:77–90PubMedCrossRef
7.
go back to reference Cai X, Garen A (1995) Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA 92:6537–6541PubMedCrossRef Cai X, Garen A (1995) Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA 92:6537–6541PubMedCrossRef
8.
go back to reference Carter P, Smith L, Ryan M (2004) Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 11:659–687PubMedCrossRef Carter P, Smith L, Ryan M (2004) Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 11:659–687PubMedCrossRef
9.
go back to reference Chin TW, Parry RL, Donahoe PK (1991) Human mullerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res 51:2101–2106PubMed Chin TW, Parry RL, Donahoe PK (1991) Human mullerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res 51:2101–2106PubMed
10.
go back to reference Coomber DW (2002) Panning of antibody phage-display libraries. Standard protocols. Methods Mol Biol 178:133–145PubMed Coomber DW (2002) Panning of antibody phage-display libraries. Standard protocols. Methods Mol Biol 178:133–145PubMed
11.
go back to reference Darst SA, Robertson CR, Berzofsky JA (1988) Adsorption of the protein antigen myoglobin affects the binding of conformation-specific monoclonal antibodies. Biophys J 53:533–539PubMed Darst SA, Robertson CR, Berzofsky JA (1988) Adsorption of the protein antigen myoglobin affects the binding of conformation-specific monoclonal antibodies. Biophys J 53:533–539PubMed
12.
go back to reference Davis CG, Jia XC, Feng X, Haak-Frendscho M (2004) Production of human antibodies from transgenic mice. Methods Mol Biol 248:191–200PubMed Davis CG, Jia XC, Feng X, Haak-Frendscho M (2004) Production of human antibodies from transgenic mice. Methods Mol Biol 248:191–200PubMed
13.
go back to reference de Kruif J, Terstappen L, Boel E, Logtenberg T (1995) Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc Natl Acad Sci USA 92:3938–3942PubMedCrossRef de Kruif J, Terstappen L, Boel E, Logtenberg T (1995) Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc Natl Acad Sci USA 92:3938–3942PubMedCrossRef
14.
go back to reference de Rock E, Taylor N (1977) An easy method of layering blood over Ficoll-Paque gradients. J Immunol Methods 17:373–374PubMedCrossRef de Rock E, Taylor N (1977) An easy method of layering blood over Ficoll-Paque gradients. J Immunol Methods 17:373–374PubMedCrossRef
15.
go back to reference Donahoe PK, Fuller AF Jr, Scully RE, Guy SR, Budzik GP (1981) Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice. Ann Surg 194:472–480PubMedCrossRef Donahoe PK, Fuller AF Jr, Scully RE, Guy SR, Budzik GP (1981) Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice. Ann Surg 194:472–480PubMedCrossRef
16.
go back to reference Donahoe PK, Swann DA, Hayashi A, Sullivan MD (1979) Mullerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. Science 205:913–915PubMedCrossRef Donahoe PK, Swann DA, Hayashi A, Sullivan MD (1979) Mullerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. Science 205:913–915PubMedCrossRef
17.
go back to reference Ellmark P, Esteban O, Furebring C, Malmborg Hager AC, Ohlin M (2002) In vitro molecular evolution of antibody genes mimicking receptor revision. Mol Immunol 39:349–356PubMedCrossRef Ellmark P, Esteban O, Furebring C, Malmborg Hager AC, Ohlin M (2002) In vitro molecular evolution of antibody genes mimicking receptor revision. Mol Immunol 39:349–356PubMedCrossRef
18.
go back to reference Fuller AF Jr, Budzik GP, Krane IM, Donahoe PK (1984) Mullerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice. Gynecol Oncol 17:124–132PubMedCrossRef Fuller AF Jr, Budzik GP, Krane IM, Donahoe PK (1984) Mullerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice. Gynecol Oncol 17:124–132PubMedCrossRef
19.
go back to reference Gould LH, Sui J, Foellmer H, Oliphant T, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, de Silva AM, Diamond MS, Koski RA, Marasco WA, Fikrig E (2005) Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 79:14606–14613PubMedCrossRef Gould LH, Sui J, Foellmer H, Oliphant T, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, de Silva AM, Diamond MS, Koski RA, Marasco WA, Fikrig E (2005) Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 79:14606–14613PubMedCrossRef
20.
go back to reference Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC et al (1993) Human anti-self antibodies with high specificity from phage display libraries. EMBO J 12:725–734PubMed Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC et al (1993) Human anti-self antibodies with high specificity from phage display libraries. EMBO J 12:725–734PubMed
21.
go back to reference Hanes J, Pluckthun A (1997) In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 94:4937–4942PubMedCrossRef Hanes J, Pluckthun A (1997) In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 94:4937–4942PubMedCrossRef
22.
go back to reference He WW, Gustafson ML, Hirobe S, Donahoe PK (1993) Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev Dyn 196:133–142PubMed He WW, Gustafson ML, Hirobe S, Donahoe PK (1993) Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev Dyn 196:133–142PubMed
23.
go back to reference Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD (2001) Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods 248:17–30PubMedCrossRef Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD (2001) Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods 248:17–30PubMedCrossRef
24.
go back to reference Hoogenboom HR, Lutgerink JT, Pelsers MM, Rousch MJ, Coote J, Van Neer N, De Bruine A, Van Nieuwenhoven FA, Glatz JF, Arends JW (1999) Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library. Eur J Biochem 260:774–784PubMedCrossRef Hoogenboom HR, Lutgerink JT, Pelsers MM, Rousch MJ, Coote J, Van Neer N, De Bruine A, Van Nieuwenhoven FA, Glatz JF, Arends JW (1999) Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library. Eur J Biochem 260:774–784PubMedCrossRef
25.
go back to reference Imbeaud S, Faure E, Lamarre I, Mattei MG, di Clemente N, Tizard R, Carre-Eusebe D, Belville C, Tragethon L, Tonkin C, Nelson J, McAuliffe M, Bidart JM, Lababidi A, Josso N, Cate RL, Picard JY (1995) Insensitivity to anti-mullerian hormone due to a mutation in the human anti-mullerian hormone receptor. Nat Genet 11:382–388PubMedCrossRef Imbeaud S, Faure E, Lamarre I, Mattei MG, di Clemente N, Tizard R, Carre-Eusebe D, Belville C, Tragethon L, Tonkin C, Nelson J, McAuliffe M, Bidart JM, Lababidi A, Josso N, Cate RL, Picard JY (1995) Insensitivity to anti-mullerian hormone due to a mutation in the human anti-mullerian hormone receptor. Nat Genet 11:382–388PubMedCrossRef
26.
go back to reference Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 4:773–783PubMedCrossRef Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 4:773–783PubMedCrossRef
27.
go back to reference Kingsbury GA, Junghans RP (1995) Screening of phage display immunoglobulin libraries by anti-M13 ELISA and whole phage PCR. Nucleic Acids Res 23:2563–2564PubMedCrossRef Kingsbury GA, Junghans RP (1995) Screening of phage display immunoglobulin libraries by anti-M13 ELISA and whole phage PCR. Nucleic Acids Res 23:2563–2564PubMedCrossRef
28.
go back to reference Kohler G, Hengartner H, Shulman MJ (1978) Immunoglobulin production by lymphocyte hybridomas. Eur J Immunol 8:82–88PubMedCrossRef Kohler G, Hengartner H, Shulman MJ (1978) Immunoglobulin production by lymphocyte hybridomas. Eur J Immunol 8:82–88PubMedCrossRef
29.
go back to reference Kohls MD, Lappi DA (2000) Mab-ZAP: a tool for evaluating antibody efficacy for use in an immunotoxin. Biotechniques 28:162–165PubMed Kohls MD, Lappi DA (2000) Mab-ZAP: a tool for evaluating antibody efficacy for use in an immunotoxin. Biotechniques 28:162–165PubMed
30.
go back to reference Krag DN, Shukla GS, Shen GP, Pero S, Ashikaga T, Fuller S, Weaver DL, Burdette-Radoux S, Thomas C (2006) Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res 66:7724–7733PubMedCrossRef Krag DN, Shukla GS, Shen GP, Pero S, Ashikaga T, Fuller S, Weaver DL, Burdette-Radoux S, Thomas C (2006) Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res 66:7724–7733PubMedCrossRef
31.
go back to reference Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, Pluckthun A (1997) Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 201:35–55PubMedCrossRef Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, Pluckthun A (1997) Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 201:35–55PubMedCrossRef
32.
go back to reference Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581–597PubMedCrossRef Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222:581–597PubMedCrossRef
33.
go back to reference Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK (1999) Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 5:3488–3499PubMed Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK (1999) Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 5:3488–3499PubMed
34.
go back to reference Matson CF (1965) Polyacrylamide gel electrophoresis. A simple system using gel columns. Anal Biochem 13:294–304PubMedCrossRef Matson CF (1965) Polyacrylamide gel electrophoresis. A simple system using gel columns. Anal Biochem 13:294–304PubMedCrossRef
35.
go back to reference McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554PubMedCrossRef McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554PubMedCrossRef
36.
go back to reference Mishina Y, Tizard R, Deng JM, Pathak BG, Copeland NG, Jenkins NA, Cate RL, Behringer RR (1997) Sequence, genomic organization, and chromosomal location of the mouse Mullerian-inhibiting substance type II receptor gene. Biochem Biophys Res Commun 237:741–746PubMedCrossRef Mishina Y, Tizard R, Deng JM, Pathak BG, Copeland NG, Jenkins NA, Cate RL, Behringer RR (1997) Sequence, genomic organization, and chromosomal location of the mouse Mullerian-inhibiting substance type II receptor gene. Biochem Biophys Res Commun 237:741–746PubMedCrossRef
37.
go back to reference Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473–482PubMed Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473–482PubMed
39.
go back to reference Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565PubMedCrossRef Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565PubMedCrossRef
40.
go back to reference Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD (2000) Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 301:1149–1161PubMedCrossRef Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD (2000) Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 301:1149–1161PubMedCrossRef
41.
go back to reference Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102:430–437PubMedCrossRef Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102:430–437PubMedCrossRef
42.
go back to reference Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK (2005) Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc Natl Acad Sci USA 102:111–116PubMedCrossRef Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK (2005) Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc Natl Acad Sci USA 102:111–116PubMedCrossRef
43.
go back to reference Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122:598–609PubMedCrossRef Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122:598–609PubMedCrossRef
44.
go back to reference Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugniere M, Pourquier D, Gutowski M, Picard JY, Xavier F, Pelegrin A, Navarro-Teulon I (2004) The anti-Mullerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J 379:785–793PubMedCrossRef Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugniere M, Pourquier D, Gutowski M, Picard JY, Xavier F, Pelegrin A, Navarro-Teulon I (2004) The anti-Mullerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J 379:785–793PubMedCrossRef
45.
go back to reference Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, Adams GP (1995) In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1:73–81PubMedCrossRef Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, Adams GP (1995) In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1:73–81PubMedCrossRef
46.
go back to reference Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks JD (1998) Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 95:6157–6162PubMedCrossRef Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks JD (1998) Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 95:6157–6162PubMedCrossRef
47.
go back to reference Skerra A (2000) Engineered protein scaffolds for molecular recognition. J Mol Recognit 13:167–187PubMedCrossRef Skerra A (2000) Engineered protein scaffolds for molecular recognition. J Mol Recognit 13:167–187PubMedCrossRef
48.
go back to reference Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT (2002) Highly purified mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 8:2640–2646PubMed Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT (2002) Highly purified mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 8:2640–2646PubMed
49.
go back to reference Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK (1996) Developmental expression of a candidate mullerian inhibiting substance type II receptor. Endocrinology 137:160–165PubMedCrossRef Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK (1996) Developmental expression of a candidate mullerian inhibiting substance type II receptor. Endocrinology 137:160–165PubMedCrossRef
50.
go back to reference Wang X, Campoli M, Ko E, Luo W, Ferrone S (2004) Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods 294:23–35PubMedCrossRef Wang X, Campoli M, Ko E, Luo W, Ferrone S (2004) Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods 294:23–35PubMedCrossRef
51.
go back to reference Watters JM, Telleman P, Junghans RP (1997) An optimized method for cell-based phage display panning. Immunotechnology 3:21–29PubMedCrossRef Watters JM, Telleman P, Junghans RP (1997) An optimized method for cell-based phage display panning. Immunotechnology 3:21–29PubMedCrossRef
52.
go back to reference Williams B, Atkins A, Zhang H, Lu D, Jimenez X, Li H, Wang MN, Ludwig D, Balderes P, Witte L, Li Y, Zhu Z (2005) Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth. Leukemia 19:1432–1438PubMedCrossRef Williams B, Atkins A, Zhang H, Lu D, Jimenez X, Li H, Wang MN, Ludwig D, Balderes P, Witte L, Li Y, Zhu Z (2005) Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth. Leukemia 19:1432–1438PubMedCrossRef
53.
go back to reference Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433–455PubMedCrossRef Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433–455PubMedCrossRef
54.
go back to reference Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP (2006) Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther 5:2096–2105PubMedCrossRef Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP (2006) Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther 5:2096–2105PubMedCrossRef
Metadata
Title
Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning
Authors
Qing-An Yuan
Matthew K. Robinson
Heidi H. Simmons
Maria Russeva
Gregory P. Adams
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-007-0376-2

Other articles of this Issue 3/2008

Cancer Immunology, Immunotherapy 3/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine